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AMP-activated protein kinase (AMPK) is a principal
metabolic regulator affecting growth and response
to cellular stress. Comprised of catalytic and regula-
tory subunits, each present in multiple forms, AMPK
is best described as a family of related enzymes.
In recent years, AMPK has emerged as a desirable
target for modulation of numerous diseases, yet
clinical therapies remain elusive. Challenges result,
in part, from an incomplete understanding of the
structure and function of full-length heterotrimeric
complexes. In this work, we provide the full-length
structure of the widely expressed a1b1g1 isoform
of mammalian AMPK, along with detailed kinetic
and biophysical characterization. We characterize
binding of the broadly studied synthetic activator
A769662 and its analogs. Our studies follow on the
heels of the recent disclosure of the a2b1g1 structure
and provide insight into the distinct molecular mech-
anisms of AMPK regulation by AMP and A769662.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a central monitor and
regulator of cellular energy status in eukaryotes. From a func-
tional perspective, conditions of energy depletion cause activa-
tion of AMPK that leads to upregulation of catabolic processes
(fatty acid oxidation and glycolysis) and a corresponding down-
regulation of anabolic processes (cholesterol and lipid synthesis
and gluconeogenesis). The net effect is to replenish ATP at times
of stress so that cellular energy balance is restored (Carling et al.,
2011; Hardie, 2007; Oakhill et al., 2012; Steinberg and Kemp,
2009). Given this central function in metabolism, AMPK has
emerged as an attractive target for diabetes and cancer (Hardie,
2013; Viollet et al., 2007). Pharmacological activation of AMPK
has long been sought as a therapeutic approach in these disor-Structure 22, 1161ders, yet clinically viable direct small molecule activators of
AMPK have to date remained elusive. This is, in part, due to
the complexity of this enzyme and the lack of detailed under-
standing of its molecular mode of action.
In recent years, there has been significant progress in eluci-
dating the structural basis of these complex and critical func-
tions. AMPK is a 145 kDa heterotrimeric serine/threonine
kinase comprised of one catalytic a subunit in complex with reg-
ulatory b and g subunits. The a subunit includes an N-terminal ki-
nase domain (KD), which is the catalytic engine of the enzyme,
and a C-terminal subunit-interacting domain (SID) that plays a
structural role in mediating interactions with b and g. Between
these regions lies an auto-inhibitory domain (AID) comprised of
a three-helical bundle, as well as regulatory motifs termed the
a regulatory subunit-interacting motifs (RIMs), which appear to
have a critical role in allosteric regulation of AMPKby nucleotides
(Chen et al., 2013; Xiao et al., 2011). a-N-myristoylation of the b
subunit may facilitate reversible binding to membranes and acti-
vation by upstream kinases (Oakhill et al., 2010; Steinberg and
Kemp, 2009; Warden et al., 2001). The unstructured N-terminal
portion of this domain is followed by a b sheet rich carbohydrate
binding module (CBM). This motif bears sequence similarity to
starch binding domains in other proteins and interacts with
glycogen and b-cyclodextrin, a cyclized form of maltoheptaose
(Polekhina et al., 2005). The most C-terminal element of the b
subunit serves as a scaffold, forming an extended b sheet with
a and g subunits within the regulatory core. Finally, the g subunit
is comprised of four tandem cystathionine b synthase (CBS) mo-
tifs, which are structural modules of 60 amino acids organized
into a two-stranded b sheet with two surrounding a helices. A
pair of CBS modules forms a ‘‘Bateman’’ domain, which pos-
sesses two nucleotide binding sites, one on each side.
The presence of multiple gene products (a1, a2; b1, b2; g1, g2,
g3) theoretically allows subunits to be mixed-and-matched to
create twelve unique heterotrimers. The distinct activities of
each complex are not fully understood, but derive, in part, from
differential expression patterns across tissues. For example,
g1 and g2 appear to be widely expressed, while g3 appears
restricted to skeletal muscle (Birk and Wojtaszewski, 2006;
Cheung et al., 2000). In addition, expression patterns may differ–1172, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1161
Structure
Structure of AMPK a1b1g1across species, as human liver predominantly contains the
a1b2g1 heterotrimer, while rat and dog livers mainly contain
a2b1g1 and a1b1g1 respectively (Wu et al., 2013). A full under-
standing of the biological function of AMPKwill require structural
characterization of the different heterotrimers and assignment of
their cell- and tissue-specific functions.
Activity of AMPK has generally been thought to require phos-
phorylation on a conserved threonine (T172) within the activation
loop by upstream kinases, LKB1, or CaMKKb, leading to >500-
fold stimulation of its activity (Hawley et al., 1996, 2005; Hurley,
et al., 2005; Shaw et al., 2004; Woods et al., 2003a, 2005). How-
ever, recent work has revealed that under certain conditions,
AMPK that is unphosphorylated on T172 of the activation loop is
still competent to phosphorylate SAMS peptide (Scott et al.,
2014). Catalytic activity can be further modulated by interactions
with adenine nucleotides in the g subunit. Binding of ATP is re-
garded as inhibitory, while AMP and ADP appear stimulatory.
Stimulation occurs principally through protection of T172 from
dephosphorylation by phosphatases, with additional allosteric
activation triggered by AMP (Gowans et al., 2013; Hardie, 2011;
Steinberg and Kemp, 2009).
The capacity to be activated by nucleotides was an original
defining feature of AMPK (Carling et al., 1989; Steinberg and
Kemp, 2009), but the first synthetic activatorwasnot reportedun-
til 2006 (Cool et al., 2006).When administered to ob/obmice, this
thienopyridone derivative, termed A769662, was observed to
lower blood glucose, decrease body weight, and reduce circu-
lating levels of triglycerides. A769662 was shown to mediate its
effects through direct interaction with AMPKwith in vitro potency
in the nanomolar range. In addition,mutagenesis andbiophysical
experiments suggested that the site of binding andmechanismof
activation differ between A769662 and AMP (Cool et al., 2006;
Go¨ransson et al., 2007; Landgraf et al., 2013; Sanders et al.,
2007; Scott et al., 2008).
Structural insights into AMPK function have been derived
largely from studies involving isolated domains or truncations.
A breakthrough came with the identification of the structure of
the regulatory core particle comprising the g subunit and C-ter-
minal portions of the a and b chains (Amodeo et al., 2007; Chen
et al., 2012; Townley and Shapiro, 2007; Xiao et al., 2007). These
studies revealed the structure of the four nucleotide binding sites
in the g subunit and set the stage for understanding differential
binding to each of these pockets (Chen et al., 2012; Kemp
et al., 2007; Xiao et al., 2007, 2011).
Despite shedding light on the topology of the g subunit, struc-
tures that lack the KD do not provide information on how nucle-
otide binding is coupled to changes in activity. In 2011, progress
toward this goal was made with the structure of a1b2g1 regula-
tory core plus the KD (Xiao et al., 2011). In addition to revealing
the location of the activation loop and active site of the a subunit
in relation to nucleotide binding sites in the g subunit, these in-
vestigations revealed that the AID of the a subunit adopts a
unique position relative to the conformation observed in a nonac-
tivated homolog from yeast (Chen et al., 2009, 2013). This allows
a flanking regulatory segment (aRIM) to directly interact with
bound nucleotides in the g subunit, establishing a line of commu-
nication between AMP and the a subunit. A landmark structure
was recently reported by Xiao et al. in December 2013 describing
the first near full-length structure of any AMPK isoform (a2b1g1)1162 Structure 22, 1161–1172, August 5, 2014 ª2014 Elsevier Ltd Al(Xiao et al., 2013). This work revealed the topology of this heter-
otrimer in a ligand-bound state and revealed a role for an intersu-
bunit interface between a2 and b1 for binding of synthetic
activators (see Results/Discussion). In this study, we extend
the collection of AMPK structures by providing the full length
structure of the a1b1g1 isoform of mammalian AMPK containing
the regulatory core, KD, and CBM. We determined structures in
the presence and absence of synthetic activators to better un-
derstand the conformations and molecular mechanisms asso-
ciated with activator binding. The crystal structures reported
herein, along with kinetic and biophysical studies, demonstrate
that AMP and A769662 engage distinct molecular mechanisms
for activation of AMPK.
RESULTS
AMP-Activated Protein Kinase a1b1g1 Adopts an
Extended Structure Capped by the Carbohydrate
Binding Module of b1
We recognized the importance of the CBM motif for activator
binding (Landgraf et al., 2013) and explored many AMPK con-
structs to achieve homogeneity with respect to posttranslational
modifications. Our final construct (AMPKxtal) is displayed in Fig-
ure 1A and represents a variant of rat a1b1g1 that includes
replacement of a previously described flexible loop in the a1 sub-
unit (Xiao et al., 2007) with a flexible linker, truncation of the first
67 residues of b1 (predicted to be unstructured), the phosphomi-
metic mutation, S108D, within the CBM of b1, and full-length g1.
The resulting heterotrimer was phosphorylated on T172 in vitro
using CaMKKb yielding a functional enzyme with activity com-
parable to full-length wild-type (WT), but nearly devoid of hetero-
geneity as assessed by mass spectrometry (Figure S1 available
online).
We crystallized AMPKxtal in the presence of AMP and stauro-
sporine, a potent kinase inhibitor, and determined the structure
at 3.4 A˚ resolution (Table 1). a1b1g1 adopts an extended confor-
mation similar to that seen for a2b1g1 (Figures 1 and 2). The a
and b subunits dock atop the g subunit where the C-terminal re-
gion of the b subunit is sandwiched between the top of the g
domain and the C-terminal region of the a subunit. The KD of
the a1 subunit is located against the core, and the activation
loop encompassing pT172 is well ordered and positioned as pre-
viously described (Xiao et al., 2011) (Figure S2A). The C-helix of
the KD adopts a conformation consistent with an active kinase in
which a critical salt bridge between K45 and E64 is intact. The
regulatory segment of the a subunit, which is partially modeled
in a2b1g1, is disordered in our structure.
The CBMof the b1 subunit sits atop the N-lobe of the KD of the
a1 subunit, where each domain contributes a b sheet in a near-
orthogonal orientation to create a clam-shell-shaped interface.
The conformation and location of the CBM is similar to that
observed for a2b1g1 (Figure 2), but differs dramatically from
that observed for the yeast homolog, where the CBMwas shown
to interact with the g subunit (Amodeo et al., 2007). The CBM-KD
interface is stabilized by electrostatic interactions between two
conserved lysines in the a1 subunit (K29, K31) and the phospho-
mimetic aspartic acid at position 108of theb1subunit (Figure 1C).
Note thatposition108 isaserine inWTAMPK,whichcanbephos-
phorylated in vivo (Mitchelhill et al., 1997; Warden et al., 2001;l rights reserved
Figure 1. Construct Design and Structure of
AMPKxtal
(A) Schematic representation of the construct used
for crystallization of AMPK a1b1g1 (AMPKxtal), a
(purple), b (cyan), and g (pink).
(B) Topology of near-full length AMPK a1b1g1.
Arrows indicate the location of the CBM-KD
interface, aC-helix and C-interacting helix, ATP
site, activation loop, and highest affinity AMP site
(site 4).
(C) Close-up view of the CBM-KD interface illus-
trating intersubunit electrostatics.
(D) Surface representation of the structure shown
in (B). The disordered segment between the b1
CBM and the C-terminal domain is shown as
dotted lines.
See also Figures S1 and S2.
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Structure of AMPK a1b1g1Woodset al., 2003b). TheS108Dmutation led to greater homoge-
neityand,consequently,was theconstruct that first enabledcrys-
tallization.We have subsequently reinstated the native S108 and,
after in vitro phosphorylation (>75% pS108), crystallized the
pS108 a1b1g1 construct and collected a data set to 3.9 A˚ resolu-
tion. Although the lower resolution precluded extensive model
building and refinement, maps were of sufficient quality to allow
visualization of the phosphate in a difference electron-density
map. The phosphate occupies a similar location as the carbox-
ylate in S108D and generates an analogous orientation of the
CBM-KD interface (Figure S2B). These observations confirm
that thea/b interface observed in theS108Dcrystals is not an arti-
fact of the phosphomimetic mutation. There is an additional
sphere of electron density visible within the CBM-KD interface
which we have modeled as a sulfate due to both its proximity to
positively charged amino acids (a1K29, a1K51, b1R83) and
the presence of > 1 M sulfate in the crystallization conditions
(Figure S3). This ion is likely a consequence of crystallization
and not of physiological or mechanistic relevance. Additional
weakdensity observed in this cavity is likely due towater or buffer
components, which have not been modeled.
The b1 subunit further contributes a novel helical motif
(recently termed the ‘‘C-interacting helix’’), which extends from
the C-terminal end of the CBM and packs against the B- and
C-helices of a1, generating a pseudo-helical bundle (Figures
1B and S2C). This helix has not been observed in previous
studies of the isolated CBM, but was recently observed in
a2b1g1 (Xiao et al., 2013). The C-interacting helix comprises res-Structure 22, 1161–1172, August 5, 2014 ªidues 162–171 and modeling resumes at
residue 201 as the structure transitions
into the core particle. There exists a
stretch of partially continuous electron
density (varying in clarity across struc-
tures), which likely accounts for a portion
of this linker. We have attempted to build
this segment, but have ultimately chosen
to exclude it from the final model, as we
were unconvinced of amino acid registra-
tion or identity.
AMPK a1 and a2 share a sequence
identity of77%, and the global architec-
ture between the a1b1g1 and a2b1g1 structures appears highly
conserved. Overall shape and topology are alike, with docking of
the CBMof the b subunit atop the KD (Figure 2A). Both structures
contain an ordered C-interacting helix which packs against the
N-lobe of a1 or a2, and both structures contain an active confor-
mation of the regulatory spine as seen in other kinases (Figure 2B)
(Taylor andKornev, 2011). Despite these similarities, these struc-
tures possess several important differences. First, although the
a2b1g1 structure contains the phosphorylated activation loop
(pT172), and is bound to an activator, a critical salt bridge be-
tween K45 and E64 in the N-lobe is broken due to displacement
of the aB and aC helices of a2 (Figure 2C). This salt bridge is
thought to be a requisite for a catalytically competent kinase
and is maintained in our a1b1g1 structures. In addition, the KD
and CBM are significantly offset with respect to the regulatory
core. This is caused by a 15 rigid body rotation near
the base of the KD (Figure 2D). With alignment based on the
N-lobe of the KD, we see that although the overall shape of the
CBM-KD interface is preserved, the b1 CBM docks differently
atop a1 versus a2 (Figure 2E). Although slight variation occurs
even within the a2b1g1 structure between the two copies in
the asymmetric unit, differences are more pronounced in com-
parisons between a1b1g1 and a2b1g1 (global root-mean-
square deviation [rmsd] 1.5 A˚).
A769662 Binds at a Novel a/b Allosteric Site
AMPK a1b1g1 was initially crystallized in the presence of
AMP, but in the absence of the synthetic activator, A769662.2014 Elsevier Ltd All rights reserved 1163
Table 1. Data Collection and Refinement Statistics
AMPK
a1b1g1 Apo
AMPK
a1b1g1 +
Cl-A769662
AMPK
a1b1g1 +
Br2-A769662
core
Data Collection
Spacegroup P6122 P6122 P6122
Unit cell dimensions (A˚) a = 124.4
b = 124.4
c = 404.0
a = 124.6
b = 124.6
c = 402.9
a = 123.9
b = 123.9
c = 401.6
Resolution (A˚) 30–3.45
(3.57-3.45)
30–3.35
(3.47-3.35)
30–3.55
(3.68-3.55)
No. of molecules in
asymmetric unit
1 1 1
No. of reflections 78,441 143,108 140,643
No. of unique reflections 24,464 27,060 20,989
Multiplicity 3.2 (2.8) 5.3 (3.5) 6.7 (6.8)
Completeness (%) 96.8 (97.4) 96.9 (80.1) 90.6 (92.6)
Rmerge (%) 10.4 (43.7) 11.5 (48.9) 14.8 (45.0)
<I/s(I)> 9.2 (2.0) 15.1 (2.0) 10.7 (3.2)
Refinement
No. of reflections for
the work data set
23,124 25,707 19,755
No. of reflections for
the test data set
1,208 1,352 1,047
R/Rfree (%) 22.2/26.7 21.0/24.9 22.6/26.9
No. of atoms protein/
water
6,491/0 6,345/0 6,008/0
Rmsd bond length (A˚) 0.01 0.01 0.01
Rmsd bond angles () 1.2 1.2 1.3
B factors (A˚2) 85 104 101
Structure
Structure of AMPK a1b1g1Examination of the g subunit reveals weak electron density in at
least three of the four nucleotide binding sites (sites 1, 3, 4). We
havemodeled an AMP at site 4 (high affinity) in all structures, but,
given the limited diffraction resolution data, we have modeled
either nucleotide or sulfate in sites 1 and 3 depending on the
quality of the electron density map (although this may actually
represent weak/partial density for nucleotide). In one instance,
we have cautiously modeled an ADP in site 1 (which is likely a
contaminant in our AMP stock), though it is conceivable that par-
tial occupancy of AMP and/or sulfate could also be present.
To characterize binding of the synthetic activator, A769662,
we turned to a chlorinated analog (termed Cl-A769662), which
differs from the parent compound by a single atom (Cl) ap-
pended directly to the thienopyridone core. Cl-A769662 binds
and activates a1b1g1 with higher affinity/potency (7-fold)
than A769662 and afforded the opportunity to obtain an acti-
vator-bound structure at 3.3 A˚ resolution through a crystal soak-
ing experiment (Figures 3 and 4A). Cl-A769662 binds to a1b1g1
at the interface between the CBMand the KD, similar to the bind-
ing site observed in the A769662 complex with a2b1g1. This site
is at the opposite pole of AMPK from the nucleotide binding sites
and contacts neither the ATP site nor activation loop of the KD.
Cl-A769662 docks such that the hydroxyl of the thienopyri-
done core is positioned to interact with K29 of a1, while the
carbonyl is positioned to form a hydrogen bond with K51 of a1.1164 Structure 22, 1161–1172, August 5, 2014 ª2014 Elsevier Ltd AlThe intervening nitrile group faces solvent and likely perturbs
the pKa of the adjacent hydroxyl, increasing its acidity. The nitro-
gen of the pyridone core donates a hydrogen bond to D88 of a1
and disrupts an electrostatic interaction between D88 (a1) and
R83 (b1) observed in the apo structure (Figures 3 and S4). The
repositioned R83 stacks4 A˚ above the Cl-A769662 core, form-
ing ap-cation interaction with the ligand, contributing to its over-
all free energy of binding. In addition, the side chain guanidinium
group of R83 forms an ion-pair with a1 D217 from a neighboring
molecule in the crystal. From the bottom, I46 of a1 forms a
pedestal upon which the 6-5 core of the ligand rests. The central
phenyl ring occupies a narrow channel, which is lined in the back
by hydrophobic residues and in the front by K31. K31 partici-
pates in two additional interactions; it simultaneously forms an
electrostatic interaction with D108 of b1 and donates a hydrogen
bond to the hydroxyl group of the phenol in the tailpiece of
Cl-A769662. This phenolic oxygen participates in a bifurcated
interaction in which it additionally donates a hydrogen bond to
the backbone carbonyl of G19 of a1. Together, a network of hy-
drophobic and polar interactions serves to anchor Cl-A769662
at the CBM-KD interface.
To better understand the structure-activity relationship of the
A769662 series and to confirm the assignment and modeling
of the allosteric binding site, we solved the structure of AMPKxtal
in the presence of a dibromo analog of A769662 (Br2-
A769662core) (Figure 4). The presence of two bromines enabled
us to collect anomalous diffraction data that allowed for unam-
biguous placement of the ligand (Figure S2D). Evaluation of the
AMPKxtal structures with Br2-A769662
core and Cl-A769662 re-
veals nearly identical poses for the thienopyridone core, confirm-
ing our previous interpretation of the electron density.
Comparison to the recent A769662-bound a2b1g1 structure
reveals that in both isoforms, the core of the ligand is positioned
with a remarkably similar pose (Figure 3C). These similarities
occur even though the a1b1g1 structure represents a soaking
experiment, while the a2b1g1 structure was generated by coc-
rystallization and is in-line with the high level of sequence identity
(93%) between the N-lobes of a1 and a2 including absolute
conservation of residues contacting ligand. As this structure
represents an improvement in resolution relative to the a2b1g1
structure with A769662 (3.35 A˚ versus 3.9 A˚), we were able to
examine the binding mode in additional detail.
Ligand Deconstruction Allows Probing of the Allosteric
Pocket
To map the importance of different regions of the allosteric
pocket for ligand binding, we investigated binding of four ana-
logs of A769662 differing in the nature of the tailpiece and
halogen appended to the core (Figure 4A). The highest binding
affinity, as determined by surface plasmon resonance (SPR) in
the presence of AMP, is observed for Cl-A769662, which pro-
vides a modest (7-fold) increase in potency relative to parent
(A769662). The small potency boost is likely explained by the
burial of the chlorine within a small hydrophobic pocket
comprised primarily of residues F90 from a1 and V81, V113,
and I115 of b1. The phenol plays a prominent role in binding
affinity through both the bifurcated hydrogen bonds with K31
and G19 of a1 and through van der Waals interactions with the
CBM and KD. As such, deletion of the phenol produces anl rights reserved
Figure 2. Comparison of a1b1g1 and
a2b1g1 Structures
(A) Overlay of a1b1g1 (color) with a2b1g1 (gray—
4CFF.pdb—all atom alignment) shown in three
views as ribbon (top) and surface (bottom).
(B) Alignment of a1b1g1 and a2b1g1 based on the
N-lobe of the KD showing residues of the regula-
tory spine.
(C) Overlay of K45-E64 salt bridge in a1b1g1 and
a2b1g1 (portion of foreground removed for clarity).
(D and E) Alignment of a1b1g1 and a2b1g1 based
on the g subunit (D) and N-lobe (E) highlighting
differences in CBM domains.
Structure
Structure of AMPK a1b1g1100-fold decrease in potency. Finally, the Br2-A769662core
possesses an intermediate potency. The bromine atom at the
para position of the central phenyl ring projects along the same
trajectory as the phenol, but is unable to fulfill hydrogen bonding.
This defect is partially rescued by the second bromine on the
thienopyridone core, which occupies the same hydrophobic
pocket as the chlorine.
Solution Studies Validate Crystallographic Observations
Prior mutagenesis studies have revealed that deletion of the
CBM or KD abolishes AMPK activation by A769662 (Go¨ransson
et al., 2007; Sanders et al., 2007; Scott et al., 2008; Xiao et al.,
2013). However, in contrast to a previous report (Scott et al.,
2008), we observe interactions between A769662 and isolated
b1 CBM in solution, albeit weak. Nuclear magnetic resonance
(NMR) TROSY experiments using 15N b1 CBM reveal a subset
of residues that undergo chemical-shift perturbations in theStructure 22, 1161–1172, August 5, 2014presence of A769662 (Figures 5A and
S5). Mapping these onto our structure
shows that the residues with the greatest
effect cluster in and around the allosteric
binding site (Figure 5A).
Close inspection shows that several
of the amino acids in this vicinity are not
conserved between b1 and b2. Although
A769662 has been observed to bind to
b2-containing heterotrimers (Landgraf
et al., 2013) and provide some protection
of pT172 from dephosphorylation (Haw-
ley et al., 2012), it is a weaker activator
of b2-isoforms in biochemical assays
(Sanders et al., 2007; Scott et al., 2008;
Xiao et al., 2013). We reasoned therefore
that generating chimeras in which we
swapped amino acids from b1 to b2
and vice versa may lead to enzymes
with altered functional specificity. Indeed,
swapping only three of the nonconserved
amino acids (F82I, T85S, and G86E) was
sufficient to greatly diminish A769662
potency toward b1, but greatly increase
potency toward b2 (Figure 5B). These chi-
meras do not fundamentally alter intrinsic
AMPK activity, as their response to AMP,which binds in the g subunit, remains largely unchanged. None of
these three amino acids directly contacts ligand. Instead, they
are proximal to or in contact with ligand-coordinating residues.
The effects of these mutations may therefore reflect subtle
changes in structure, dynamics, or topology of the CBM-KD
interface that differ between b1 and b2.
We next assessed the relative importance of interface electro-
statics. First, we generated a triple mutant in which the three
interface lysines of the a subunit were converted to glutamines
(K29-31-51Q) and assayed this mutant side-by-side with WT
AMPK. Heterotrimeric K29-31-51Q retained intrinsic activity
comparable toWT a1b1g1 (data not shown), but failed to interact
with A769662 up to the highest concentration tested (1 mM) (Fig-
ure 6). This result is similar to mutagenesis data reported for the
a2b1g1 isoform (Xiao et al., 2013). Next, we investigate an earlier
report demonstrating that mutation of serine 108 to alanine
(S108A) greatly diminishes interaction with A769662 (Sandersª2014 Elsevier Ltd All rights reserved 1165
Figure 3. A769662 Binding at CBM-KD Interface
(A) Allosteric (CBM-KD interface) within the Cl-A769662-bound structure.
Electron density is shown over the ligand (blue mesh) for a 2fo-fc map con-
toured at 1 s. Two views are shown for clarity.
(B) Zoom in of the allosteric site indicating a subset of protein-ligand
interactions.
(C) Overlay of ligand conformation for Cl-A769662 (yellow) with A769662 from
a2b1g1 (4CFF.pdb gray). Structures were aligned based on N-lobe of the KD,
only a1b1g1 shown for clarity.
See also Figures S2–S4.
Figure 4. Binding Affinity of A769662 and Analogs
(A) Chemical structure of A769662 and its analogs.
(B) SPR binding data for AMPK a1b1g1with compounds from part A and AMP.
Errors denote ± SE of the fit. #Kinetic fits for A769662 and Cl-A769662 were
obtained by a global fit using at least three concentrations in duplicate; Kd
determined by the standard equation, Kd = koff/kon; *remaining ligands were
evaluated in equilibrium bindingmode in duplicate yielding Kd, as rapid binding
precluded kinetic analysis (see Supplemental Experimental Procedures);
n/a = not applicable
Structure
Structure of AMPK a1b1g1et al., 2007). We expanded this result by performing a more con-
servative comparison between serine and phospho-serine at po-
sition 108, reflecting the two likely chemical forms of this residue
in vivo (Mitchelhill et al., 1997). In short, we performed in vitro
phosphorylation reactions of AMPK and quenched the reaction1166 Structure 22, 1161–1172, August 5, 2014 ª2014 Elsevier Ltd Alat distinct time points to generate samples of protein that were
highly phosphorylated on T172 within the activation loop of the
a1 subunit, but varied in the extent of phosphorylation on S108
of b1. In contrast to the S108A mutation, which nearly abolished
activation, AMPK reagents with S108 or pS108 appear to
respond to A769662 to similar extent (Figure S6).l rights reserved
Figure 5. NMR TROSY Experiments and
Chimeric Constructs Localize A769662 to
One Surface of the b1-CBM
(A) 2D TROSY [15N-1H] spectra of 15N b1-CBM at
5 mg/ml in the absence (black) and presence (red)
of 400 mM A769662. A subset of shifted reso-
nances is labeled in the spectra. Residues with
chemical shift differences >2 SD from the mean
(80, 81, 82, 83, 111, 114, 116, 158) are displayed
as red spheres (Ca) on the structure of AMPKxtal in
the presence of Cl-A769662 (right panel). Residue
78 also shows significant chemical shift pertur-
bations, but is not modeled in the structure.
(B) View of the allosteric interface similar to panel
(A), with amino acids 80–90 (corresponding to the
first b strand and loop of the CBMmotif) displayed
as sticks. Residues that differ between b1 and b2
(80, 85, 86) are colored orange and correspond to
the amino acids mutated in chimeras. Table on the
right displays AC50 values of A769662 and AMP
for WT enzymes a1b1g1 and a1b2g1, as well as
chimeras a1b1g1 (F82I/T85S/G86E) and a1b2g1
(I82F/S85T/E86G). n/a = not applicable.
See also Figures S5 and S6.
Structure
Structure of AMPK a1b1g1Lastly, we generated a set of AMPK truncation variants to
probe the extent to which activation by AMP and A769662 are
dependent on regulatory domains (Figure S6). Deletion of the
CBM of the b1 subunit does not alter activation by AMP, consis-
tent with the known location of nucleotide binding sites in the
g subunit. In contrast, A769662 is unable to activate the DCBM
variant, in agreement with prior reports (Go¨ransson et al.,
2007; Sanders et al., 2007; Scott et al., 2008; Xiao et al., 2013)
and in support of our crystallographic observations of the allo-
steric binding site at the CBM-KD interface. We generated an
additional variant termedDaRIM, in which we deleted a 62 amino
acid segment (333–394) in the a subunit comprising aRIM1/2,
along with flanking amino acids. The deleted segment was re-
placed with a nine-amino acid (AAGGPGGAA) linker, yielding a
well behaved heterotrimer with intrinsic activity similar to WT
(Figure S6). While this variant was fully activated by A769662, it
was largely insensitive to activation by AMP, consistent with pre-
vious site-directed mutagenesis (Chen et al., 2009).
A769662 and AMP Exert Distinct Kinetic Effects
on AMPK
To probe the kinetic mechanism, we performed in vitro assays
monitoring the phosphorylation of a model peptide substrate
(SAMS peptide) derived from acetyl-CoA carboxylase 1 (Davies
et al., 1989). Experiments were performed under saturating con-
centrations of ATPwhile varying the concentration of SAMSpep-
tide in the presence or absence of AMP or A769662 (Figure 7A).
Though effects of AMP are complicated by the presence of mul-
tiple binding sites and potential interactions of ATP at these sites,
we nevertheless observe 2-fold increase in reaction Vmax with
no effect on Km for SAMS peptide. This result is similar to anStructure 22, 1161–1172, August 5, 2014 ªobservation made by Carling et al. nearly
25 years ago (Carling et al., 1989). In
contrast, A769662 mediates its effect pri-
marily through decreasing Km (for SAMSpeptide) 4-fold, while exerting only a modest (1.4-fold) effect
on Vmax. We also performed the reverse experiment where we
used saturating levels of SAMS peptide while varying the ATP
concentration. In this case, neither AMP nor A769662 had a sig-
nificant effect on the Km of ATP (data not shown). Figure 7B
shows the location of the allosteric site relative to the previously
mapped substrate binding groove (Scott et al., 2002).
DISCUSSION
The importance of the synthetic activator A769662 for the AMPK
field is evident from the > 300 citations garnered since its initial
disclosure in 2006 (Cool et al., 2006). Despite a decade of ad-
vances in AMPK structural biology, the binding site for this ligand
has remained elusive. Early studies following the A769662
disclosure discovered that the CBM of the b subunit was neces-
sary for its interaction. Furthermore, a preference was noted for
b1 over b2, and a hot spot within this domain was identified to lie
at or near S108 (Go¨ransson et al., 2007; Sanders et al., 2007;
Scott et al., 2008). However, inspection of structures of the iso-
lated CBM motif revealed that S108 lies at a solvent-exposed
surface that reveals no obvious pocket (Polekhina et al., 2005).
Consistent with this observation, the CBM domain alone is inca-
pable of high affinity binding of A769662 as shown previously
(Scott et al., 2008) and as indicated by weak interactions in our
current solution NMR studies. A clue to the A769662 binding
site emerged from recent work in which we investigated full-
length AMPK in solution by hydrogen-deuterium exchange
(HDX) methods (Landgraf et al., 2013). Comparison of the HDX
profiles in the presence and absence of A769662 revealed
that in addition to the b1 CBM, significant perturbations were2014 Elsevier Ltd All rights reserved 1167
Figure 6. Role of Interface Lysines in Ligand Coordination
(A) Location of the three mutated lysines, K29, K31, K51 from the a1 subunit in relation to the Cl-A769662.
(B) SPR binding response of A76992 toWT AMPK a1b1g1 in duplicate at concentrations of 1 mM, 333 nM, 111 nM, and 37 nM (left) and to K29/31/51Q a1b1g1 at
N = 1 and concentrations of 1 mM, 333 nM, 111 nM, and 37 nM.
See also Figure S6.
Structure
Structure of AMPK a1b1g1observed for a peptide in the N-lobe of the a1 KD, implicating its
role for ligand binding. These HDX studies suggested that
A769662 is likely to bind at the CBM-KD interface (Landgraf
et al., 2013). This was recently confirmed by the crystal struc-
tures of compound 991 and A769662 bound to a2b1g1 that re-
vealed a novel allosteric pocket (Xiao et al., 2013).
With ligand-bound structures in hand, we can begin to
more fully understand historical observations. Although of critical
importance, the CBM provides only one half of the binding site.
For the allosteric pocket to form, both CBM and KDmust be pre-
sent as the ligand binds at the interface between them. Given the
architecture of the AMPK heterotrimer, with the KD and CBM
emanating separately from the regulatory core, only a full-length
structure containing core, KD, and CBM could allow such an
interface to assemble. Therefore, despite the important insights
gained from many years of structural studies of AMPK frag-
ments, subunits, and subcomplexes, none of these systems
contained all the necessary pieces to visualize A769662 binding.
The crystallographically observed binding site is supported by
a wealth of solution studies. First, using truncation constructs,
we find that the b1-CBM is essential for AMPK activation by
A769662 (Figure S6), consistent with prior reports (Go¨ransson
et al., 2007; Sanders et al., 2007; Scott et al., 2008; Xiao
et al., 2013). Our 2D-NMR experiments show that addition of
A769662 alters the chemical shifts of a small subset of CBM res-
idues, which cluster around the allosteric site (Figures 5 and S5).
As A769662 preferentially activates b1-containing AMPK com-
plexes (Sanders et al., 2007; Scott et al., 2008), we reasoned
that specificity is likely affected by CBM residues proximal to
this interface. Indeed, chimeras in which residues from this
surface are swapped between b1 and b2 demonstrate altered
ligand specificity (Figure 5). On the other side of the interface,
we see a collection of electrostatic interactions involving
three surface lysines, K29/31/51 with both A769662 and the
b1-CBM. These amino acids are conserved between a1 and
a2 and are retained in species ranging fromworm toman. Finally,
SPR binding studies of A769662 analogs reveal structure-
activity relationships consistent with the observed binding
mode (Figures 3 and 4).1168 Structure 22, 1161–1172, August 5, 2014 ª2014 Elsevier Ltd AlOur apo and holo a1b1g1 structures complement the recent
disclosure of the structure of a2b1g1 bound to A769662 (Xiao
et al., 2013) and begin the process of elucidating the structural
basis of subtype-specific functions of different forms of AMPK.
Although the previous reported structure of a2b1g1 with a
different AMPK activator (compound 991) was at 3.0 A˚ resolu-
tion, the structure with A769662 was at considerably lower res-
olution (3.9 A˚). Comparison of the two isoforms (and both apo
and holo structures) reveals a similar interface between the
KD and CBM involving electrostatic interactions between pS/
D108 of the b subunit and K31/K29 of the a1 and a2 subunits,
as well as a conserved conformation of the recently identified
C-interacting helix. As the C-interacting helix forms a bundle
with the aB and aC helices, we postulate that formation of
this motif is dependent on maintenance of the a/b interface
and is unlikely to be structured if the CBM dissociates. Finally,
in both isoforms, the thienopyridone core of the ligand is posi-
tioned with a similar pose despite the fact that our ligand was
modeled independently and prior to publication of the a2b1g1
structure (Figure 3C).
Despite these similarities, these structures possess several
important differences. First, in the a2b1g1 structure a critical
salt bridge in the KD (K45–E64) is broken, while it is maintained
in our apo and ligand-bound a1b1g1 structures. In addition,
with respect to the regulatory core, the position of the KD and
CBM are significantly offset (Figure 2). A third difference lies in
the AID/a-RIM regulatory motif of the a subunit. In the a2b1g1
structure, this motif adopts a conformation similar to that previ-
ously observed in the structure of the regulatory core + KD (Chen
et al., 2013; Xiao et al., 2011). In our a1b1g1 structures, this reg-
ulatory segment is disordered, providing further support that it
may sample an ensemble of conformations. Nevertheless, the
observed conformation of the C-interacting helix allows us to
rule out the possibility that the AID adopts the structure seen pre-
viously in an inactive homolog from yeast (Chen et al., 2009)
(Figure S7).
The observed structural differences could be due to crystal
packing or may reflect true diversity in the conformations of
the a1b1g1 versus a2b1g1 isoforms. In addition, this may simplyl rights reserved
Figure 7. Kinetic Effects of A769662 and AMP on Phosphorylation of
SAMS Peptide
(A) AMPK kinase activity was determined by measuring incorporation of
33phosphate from [33Pg]ATP into the SAMS peptide substrate at saturating
ATP (200 mM) and varying concentrations of SAMS peptide. Experiments were
run in the absence (DMSO) and presence of 10 mM AMP or 10 mM A769662.
(B) View of substrate binding cleft of AMPK. In yellow are seven residues (D56,
E100, D103, L212, D215, D216, D217) from previous mutation analysis used to
map substrate binding (Scott et al., 2002).
Errors denote ± SD of the fit. See also Figure S7.
Structure
Structure of AMPK a1b1g1reflect structural plasticity within the many moving parts of this
molecular machine such that we observe two states among
the multitude of possible conformations. Understanding these
differences may provide unique opportunities for the design of
isoform-specific activators.Structure 22, 1161In this work, we determined the first structure of mammalian
AMPK with all functional domains in the absence of a synthetic
activator (apo). This structure reveals that the CBM is able to
dock atop the KD even in the absence of ligand and demon-
strates that binding of A769662, or other potent ligands, is not
a prerequisite for formation of the allosteric site. Rather, the
CBM-KD interface represents one of many naturally occurring
conformations of AMPK in solution. This is consistent with recent
work establishing that the autophosphorylation of S108 occurs in
cis, i.e., phosphorylation occurs within a heterotrimeric complex
(Scott et al., 2014). As Ser 108 of the b subunit in the present
structure lies outside the substrate binding groove, flexibility
and rearrangement must occur for cis auto-phosphorylation to
take place.
Our crystallographic and solution studies suggest fundamen-
tally different molecular mechanisms of AMPK activation elicited
by A769662 and AMP. The AMP binding sites on the g subunit
are50 A˚ away from pThr172 on the activation loop of the a sub-
unit KD. There are distinct structural changes that are observed
in the g subunit, especially around site 3 between ATP- and
AMP-bound forms. These perturbations are likely to result in
altered conformation of the a-RIM, which forms direct interaction
with the g subunit near this site (Chen et al., 2013; Xiao et al.,
2011, 2013). These perturbations are in turn conveyed to the
activation loop of the kinase by long-range allosteric effects via
the AID module. Consequently, the pThr172 site becomes less
accessible to phosphatases on binding of AMP, which may
account for the observed protection from dephosphorylation.
In addition, our kinetic studies show that AMP increases the
Vmax of the phosphorylation reaction and may help fine-tune
the kinase for optimized phosphoryl-transfer.
In contrast, the binding site for A769662 is located only 20 A˚
from the pThr172 site within the activation loop. Binding of
A769662 at the allosteric site is likely to stabilize the active
conformation of the B- and C-helices of the KD via the C-inter-
acting helix. This may also help displace the AID from the KD
to relieve a previously described auto-inhibition event (Chen
et al., 2009) (Figure S7). Our kinetic data show that A769662 ac-
tivates AMPK by lowering the Km for SAMS peptide (4-fold)
with only a small effect on the reaction Vmax. Although the limited
diffraction resolution of our structures does not allow for a
detailed analysis of the structural differences, the kinetic data
imply that binding of A769662 leads to subtle structural changes
that result in a more optimal binding of the SAMS peptide.
Another possible explanation is that binding of A769662 shifts
the equilibrium toward the active conformation of AMPK via
stabilization of the CBM-KD interface. Both of these explana-
tions are consistent with recent results showing that A769662
protects portions of the substrate binding site from exchange
with deuterium (Landgraf et al., 2013). Regardless, the molecular
mechanism that underlies AMPK activation by the synthetic acti-
vator A769662 is radically different from that employed by the
endogenous activator, AMP.
It is tempting to speculate that in addition to A769662, other
ligands might take advantage of this site to bind and modulate
AMPK activity. Recently, it has been shown that salicylate, an
active metabolite of aspirin, binds to and directly activates
AMPK in a manner that is competitive with A769662 (Hawley
et al., 2012). Although wewere unable to obtain a high-resolution–1172, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1169
Figure 8. Salicylate Binding at the Allosteric Site
Anomalous difference map at 3.9 A˚ resolution contoured at 4 s. Crystal of
AMPKxtal was soaked with 2 mM 5-iodosalicylate overnight before flash
freezing. The strongest peaks in the asymmetric unit localize to the allosteric
site. 2fo-fc density was not sufficient to permit modeling of the compound.
Structure
Structure of AMPK a1b1g1structure of AMPK with salicylate bound, anomalous diffraction
data from an iodinated variant (5-iodosalicylate) supports that
salicylate binds at the CBM-KD interface (Figure 8). The experi-
mental electron density for the iodine lies just below the pS/D108
loop and would roughly overlay with the position of the phenol of
Cl-A769662 in our structure. While the identification of a physio-
logical ligand for the CBM-KD allosteric site remains to be
revealed, we hypothesize that AMPK may be a broad energy
sensor, responding to changes in levels of nucleotides, carbohy-
drate, and other metabolic mediators.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
AMPK a1b1g1was cloned into a tricistronic vector containing aHis-tag at theN
terminus of the a subunit (Neumann et al., 2003; Rajamohan et al., 2010). Con-
structs were generated using standard molecular biology techniques and are
described as follows: The a chain of AMPKxtal was comprised of a 22-residue
N-terminal tag (MPRAHHHHHHAAGENLYFQGAT) that included an initation
Met, a hexahistidine-tag, and a tobacco etch virus (TEV) protease cleavage
site, followed sequentially by residues 2–469 of GenBank accession code
U40819.1, an eight-residue linker (ASGGPGGS), and residues 525–548 of
GenBank accession U40819.1. The b1 chain was comprised of an initiator
methionine followed by residues 68–270 of UniProt accession P80386, except
that S108 was mutated to D. The sequence of the g chain was identical to the
330-residuesequenceofUniProt accessionP80358.Biochemical andbiophys-
ical experiments used full-length human AMPK a1b1g1 with an N-terminal His-
tag on the a subunit. For SPR binding experiments, an additional biotinylated
biotin-acceptor-peptide (BAP) was included at the N terminus of the g subunit.
For expression, plasmids were transformed into E. coli BL21-CodonPlus cells
grown at 37C and induced with 0.1 mM isopropyl b-D-1-thiogalactopyrano-
side at 18C overnight. Cell pellets were resuspended in 25 mM Tris 7.5,1170 Structure 22, 1161–1172, August 5, 2014 ª2014 Elsevier Ltd Al300 mM NaCl, 10% glycerol, 2 mM phosphanetriyltripropanoic acid (TCEP),
40 mM imidazole, and lysed by three passages through a microfluidizer at
18k pounds per square inch. Lysate was cleared by centrifugation, passed
over HiTrapNi-NTA resin, and elutedwith imidazole. Proteinwas dialyzed over-
night in the presence of TEV protease to remove the His-tag (only for crystalli-
zation). AMPKwasphosphorylatedwithCaMKKb in thepresenceof calmodulin
andMg-ATP and subsequently purified over Ni-NTA (activity assays) or ion ex-
change and size-exclusion chromatography (crystallography and biophysics).
Purity was assessed by SDS-PAGE and mass spectrometry (Figure S1).
Crystallization and Refinement
AMPKxtal at10–15 mg/ml in 25 mM Tris 7.5, 150mMNaCl, 2 mM TCEP, 10%
glycerol, was incubated with 400 mM of both AMP and staurosporine for
10minon ice. Thismixturewas thencentrifugedandmixed1:1withwell buffer
(750 mM ammonium sulfate, 500 mM lithium sulfate, 100 mM trisodium
citrate, 1% ethylene glycol) in sitting drops and incubated at 22C. Crystals
appeared after 3–7 days and were frozen in mother liquor plus 30% glycerol.
Data were collected at IMCA-CAT and GMCA-CAT at Advanced Photon
Source (APS) as well as beamline 5.0.1 at Advanced Light Source. Data sets
were processed using HKL2000 (Otwinowski and Minor, 1997). The structure
was determined bymolecular replacement using PHASER (McCoy et al., 2007)
with domains derived from 2Y94.pdb (Xiao et al., 2011) and 1Z0M.pdb (Pole-
khina et al., 2005) as search models. Refinement and rebuilding were carried
out using autoBUSTER (Blanc et al., 2004), PHENIX (Adams et al., 2010),
and Coot (Emsley and Cowtan, 2004), and figures were generated using
PyMOL (Schrodinger, version 1.2r3pre).
For the structures in the presence of Cl-A769662 and Br2-A769662
core,
crystals were soaked overnight in mother liquor with 500 mM ligand,
400 mM AMP, and 200 mM staurosporine, along with 10% glycerol. Crystals
were frozen in this soak solution supplemented with 30% glycerol, and the
structure was solved by molecular replacement using the apo structure as a
search model.
Kinase Activity Measurements
The kinase activity of recombinant AMPK samples was monitored in vitro by
phosphorylation of the SAMS peptide as previously described (Rajamohan
et al., 2010). Where described, AC50 values reported for A769662 and AMP
were measured in the presence of 0.25 nM AMPK in assay buffer, and all
experiments were performed in triplicate with each half maximal activating
concentration (AC50) value representing the mean of three experiments.
Steady state kinetic parameters were determined by measuring the kinase
activity of AMPK via AMPK-mediated incorporation of 33P-phosphate from
[33Pg]ATP into the synthetic SAMS peptide (Davies et al., 1989). This peptide
has the amino acid sequence HMRSAMSGLHLVKRR and is derived from res-
idues 73–85 of rat acetyl-CoA carboxylase 1 in which Ser77 is mutated to Ala
and the phosphorylation site is Ser79. Under acidic conditions, the phosphor-
ylated product was retained on the filter via charge interaction while [33P]ATP
was removed by filtration. Captured product was thenmeasured by coincident
liquid scintillation counting using a PerkinElmer MicroBeta Trilux. Standard ki-
nase reactions were performed in assay buffer consisting of 50 mM HEPES,
pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.25 mM dithiothreitol, 0.01% Tween-
20, and 0.01% BSA. There were eight concentrations of the SAMS peptide
substrate that were tested in a serial one-to-one dilution scheme, while keep-
ing ATP fixed at 10-fold the KM-value (200 mM) with and without 10 mMAMP or
10 mM A769662. The specific activity of [33P]ATP was maintained at 0.25 mCi/
nmol. These assays were assembled by the addition of 30 ml of AMPK to 10 ml
of a 4-fold concentrated substratemix. Assay linearity was ensured in separate
experiments by determining that < 30% substrate was depleted for all concen-
trations tested. The reactions were incubated for 60 min at room temperature
and were terminated by the addition of 15 ml of 2% phosphoric acid, followed
by washing three times with 100 ml assay buffer containing 0.1% Tween-20.
Plates were allowed to dry prior to the addition of 25 ml of Ready Safe scintil-
lation fluid (141329, BeckmanCoulter), followed by liquid scintillation counting.
Surface Plasmon Resonance Experiments
Experiments were performed on aBiacoreTM 3000 instrument (GEHealthcare).
BAP-tagged AMPK a1b1g1 was captured onto a streptavidin sensor chip to
levels ranging from 4,000–6,000 response units. Binding experiments werel rights reserved
Structure
Structure of AMPK a1b1g1performed in 25 mM Tris, pH 7.5, 150 mM NaCl, 250 mM TCEP, 0.01% P20,
0.5 mg/ml BSA, 2% DMSO and ± 150 mM AMP at 25C (Supplemental Exper-
imental Procedures).
Nuclear Magnetic Resonance Spectroscopy
The NMR TROSY spectra were collected on a Bruker spectrometer equipped
with a 1.7 mm micro cryoprobe operating at 600.33 MHz. The NMR samples
contained5mg/ml of 15Nuniformly labeled b1CBM in25mMphosphatebuffer,
pH 7.5, and 0.02% sodium azide (Supplemental Experimental Procedures).
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